Syndax Pharmaceuticals, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
SNDX Nasdaq 2836 syndax.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Syndax Pharmaceuticals, Inc.

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - Jul 2nd, 2025 2:01 pm
Syndax Announces FDA Priority Review of sNDA for Revuforj® (revumenib) in Relapsed or Refractory mNPM1 Acute Myeloid Leukemia - Jun 24th, 2025 2:01 pm
Syndax Pharmaceuticals Publishes Positive Revumenib Data from BEAT AML Trial - Jun 24th, 2025 10:45 am
Syndax reports publication of revumenib data from BEAT AML trial - Jun 13th, 2025 10:10 am
Syndax Announces Publication of Revumenib Data from the BEAT AML Trial in the Journal of Clinical Oncology and Simultaneous Presentation at EHA 2025 - Jun 12th, 2025 10:02 am
Syndax Presents New Revuforj® (revumenib) Data in Relapsed/Refractory mNPM1 and NUP98r Acute Leukemia from AUGMENT-101 Trial at EHA 2025 - Jun 12th, 2025 5:00 am
Syndax Announces Participation in June Investor Conferences - May 29th, 2025 5:00 am
Syndax Announces Data Presentations at EHA 2025 Showcasing Revuforj® (revumenib) and Niktimvo™ (axatilimab-csfr) - May 14th, 2025 7:30 am
Syndax Pharmaceuticals Appoints Dr. Nicholas Botwood as Head of Research and Development and Chief Medical Officer - May 12th, 2025 2:01 pm
Wall Street Analysts See a 219.98% Upside in Syndax (SNDX): Can the Stock Really Move This High? - May 9th, 2025 7:55 am
Syndax Announces Participation in May Investor Conferences - May 8th, 2025 5:00 am
Syndax Announces Publication of Pivotal Revumenib Data in Relapsed or Refractory mNPM1 Acute Myeloid Leukemia in the Journal Blood - May 7th, 2025 2:01 pm
Syndax Pharmaceuticals Inc (SNDX) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and ... - May 6th, 2025 1:06 am
Syndax Pharmaceuticals (SNDX) Reports Q1 Loss, Tops Revenue Estimates - May 5th, 2025 3:10 pm
Syndax: Q1 Earnings Snapshot - May 5th, 2025 2:08 pm
Syndax Reports First Quarter 2025 Financial Results and Provides Business Update - May 5th, 2025 2:01 pm
Syndax to Announce First Quarter 2025 Financial Results and Host Conference Call and Webcast on May 5, 2025 - Apr 28th, 2025 5:00 am
Syndax Announces Participation at the Stifel 2025 Virtual Targeted Oncology Forum - Apr 2nd, 2025 5:00 am
Syndax Pharmaceuticals Inc (SNDX) Q4 2024 Earnings Call Highlights: Strong Product Launch and ... - Mar 5th, 2025 8:00 am
Syndax Pharmaceuticals (SNDX) Reports Q4 Loss, Lags Revenue Estimates - Mar 3rd, 2025 6:15 am